PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216346 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Caterina Mancarella und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy. Hauptthemen laut MEDLINE: Sarcoma, Soft Tissue Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.
Abstract (Originalsprache)
Sarcomas are heterogeneous bone and soft tissue cancers representing the second most common tumor type in children and adolescents. Histology and genetic profiling discovered more than 100 subtypes, which are characterized by peculiar molecular vulnerabilities. However, limited therapeutic options exist beyond standard therapy and clinical benefits from targeted therapies were observed only in a minority of patients with sarcomas. The rarity of these tumors, paucity of actionable mutations, and limitations in the chemical composition of current targeted therapies hindered the use of these approaches in sarcomas. Targeted protein degradation (TPD) is an innovative pharmacological modality to directly alter protein abundance with promising clinical potential in cancer, even for undruggable proteins. TPD is based on the use of small molecules called degraders or proteolysis-targeting chimeras (PROTACs), which trigger ubiquitin-dependent degradation of protein of interest. In this review, we will discuss major features of PROTAC and PROTAC-derived genetic systems for target validation and cancer treatment and focus on the potential of these approaches to overcome major issues connected to targeted therapies in sarcomas, including drug resistance, target specificity, and undruggable targets. A deeper understanding of these strategies might provide new fuel to drive molecular and personalized medicine to sarcomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
ORCID-Profile: Caterina Mancarella, Andrea Morrione, Katia Scotlandi
Förderung
- Ministero della Salute
- Italian Ministry of Health
Zitieren
APA
Mancarella, C., Morrione, A., & Scotlandi, K. (2023). PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216346
Vancouver
Mancarella C, Morrione A, Scotlandi K. PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216346
BibTeX
@article{Mancarella2023,
author = {Mancarella, Caterina and Morrione, Andrea and Scotlandi, Katia},
title = {PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216346}
}
EUVIMED